Agios Pharmaceuticals Inc. obtained its second approval for a targeted acute myelogenous leukemia drug in less than a year and will soon launch Tibsovo (ivosidenib) for relapsed or refractory AML patients who test positive for an IDH1 mutation. The firm said on July 20 that it set a 30-day wholesale acquisition cost of $26,115 for the drug at a daily dose of 500 mg.
Cambridge, Mass.-based Agios and partner Celgene Corp. won US FDA approval of Idhifa (enasidenib) for the treatment of relapsed or refractory AML patients with an IDH2 mutation in August of last year; that drug launched at $24,872 per month. (Also see "Celgene, Agios Ready For Enasidenib Launch After Early Approval" - Scrip, 1 August, 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?